Edition:
United Kingdom

People: Prometic Life Sciences Inc (PLI.TO)

PLI.TO on Toronto Stock Exchange

0.07CAD
5:00pm BST
Change (% chg)

$0.00 (+7.69%)
Prev Close
$0.06
Open
$0.07
Day's High
$0.07
Day's Low
$0.06
Volume
835,896
Avg. Vol
2,303,808
52-wk High
$1.01
52-wk Low
$0.05

Kenworthy, Charles 

Mr. Charles N. Kenworthy is Non-Independent Director of the Company. Mr. Charles N. Kenworthy is Executive Vice-President, Corporate Strategy, NantWorks, LLC since 2011 and President of Nant Capital, LLC. Mr. Kenworthy received his Bachelor of Arts from the University of California, Los Angeles, in 1980 and his Juris Doctorate from the University of San Diego School of Law in 1985. He joined the law firm of Allen Matkins in the mid-1980's and was a partner when he departed in 2006. Thereafter, he joined Abraxis Biosciences, LLC as Executive Vice-President, Corporate Strategy. Mr. Charles N. Kenworthy was nominated to the Board by California Capital Equity, LLC ("CCE") (an affiliate of Abraxis Bioscience International Holding Company, Inc.), pursuant to a securities purchase agreement (the "Purchase Agreement") entered into between the Corporation and Abraxis Bioscience International Holding Company, Inc. on September 3, 2008. Pursuant to the Purchase Agreement, CCE is entitled to nominate one person for election to the Board.

Basic Compensation

Total Annual Compensation, CAD 38,700
Restricted Stock Award, CAD --
Long-Term Incentive Plans, CAD --
All Other, CAD 84,409
Fiscal Year Total, CAD 123,109

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Simon Best

277,333

Bruce Pritchard

2,711,580

John Moran

1,837,760

Bruce Wendel

121,072

Patrick Sartore

2,119,760

Stefan Clulow

121,072
As Of  31 Dec 2017